Conflu3nce
Personalized Solution for Detecting Cognitive Health Changes
Company Overview
Snapshot
Founded in April 2016 by Tami Ellison, Conflu3nce operates with 1–10 employees. The company has raised $330,000 across two funding rounds from one investor, with PSC, LLC participating. Conflu3nce holds a patent for its methods in early detection of cognitive health changes.
Business overview
Conflu3nce specializes in health technology, applying patented methods for the early detection of cognitive health changes across various conditions, including Alzheimer's disease, traumatic brain injury, and Parkinson's disease. The company is developing PICSSi, a minimally-disruptive, on-demand system that addresses cognitive-motor issues. Its core technology, PICSSi and Stitch and Peel (SnP), utilizes content-rich, dynamic, 3D-like figure-ground image sets for personalized cognitive expression pattern capture and skill remediation. Conflu3nce serves global markets with business models spanning B2B, B2C, and B2B2C, operating within the Digital Health and Medical Technologies sector.
Log in to access full profile ›Company Intelligence Q&A
- What is Conflu3nce's core technology?
- Conflu3nce utilizes patented methods to develop PICSSi and Stitch and Peel (SnP) technology. This technology is based on processes that use content-rich, dynamic, 3D-like figure-ground image sets with manipulable and predictable image properties, designed for personalized interactive units.
- When was Conflu3nce founded?
- Conflu3nce was founded in April 2016.
- What is the primary application of Conflu3nce's technology?
- Conflu3nce's technology is primarily applied to the early detection of cognitive health changes and addressing cognitive-motor issues in individuals with conditions such as Alzheimer's disease, traumatic brain injury, Parkinson's disease, stroke, and ADHD.
- Which markets does Conflu3nce target?
- Conflu3nce targets global markets, serving patients, healthcare providers, and pharma companies within the digital healthcare and digital therapeutics sectors.
- Has Conflu3nce received any grants?
- In March 2020, Conflu3nce received a grant from the Jerusalem Development Authority.